...
首页> 外文期刊>癌と化学療法 >Gene therapy for breast cancer
【24h】

Gene therapy for breast cancer

机译:乳腺癌的基因治疗

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Breast cancer is sensitive to chemotherapy and endocrine therapy, but the prognosis of advanced or relapsed breast cancer is unsatisfactory. Gene therapy is promising as another useful therapeutic approach for advanced breast cancer. Strategies of gene therapy for breast cancer in ongoing clinical protocols can be divided into four: (1) suppression of oncogenes or transduction of tumor suppressors; (2) enhancement of immunological response to cancer cells; (3) transduction of suicide genes; and (4) protection of bone marrow using drug resistance genes. We have started a clinical study of gene therapy for breast cancer using multidrug resistance gene (MDR1), in which advanced or relapsed breast cancer patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with MDR1-transduced hemopoietic cells, and then were treated with docetaxel. Two patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment after PBSCT was seen in both cases. Both patients are in complete remission and have no apparent adverse effect from MDR1 gene transduction.
机译:乳腺癌对化学疗法和内分泌疗法敏感,但是晚期或复发性乳腺癌的预后并不令人满意。基因治疗有望成为晚期乳腺癌的另一种有用的治疗方法。正在进行的临床方案中的乳腺癌基因治疗策略可分为四类:(1)抑制癌基因或转导肿瘤抑制因子; (2)增强对癌细胞的免疫反应; (3)自杀基因的转导; (4)利用耐药基因保护骨髓。我们已经开始使用多药耐药基因(MDR1)对乳腺癌进行基因治疗的临床研究,其中晚期或复发性乳腺癌患者接受了大剂量化疗和MDR1诱导的造血细胞自体外周血干细胞移植(PBSCT),以及然后用多西他赛治疗。到目前为止,已有两名患者接受了治疗,在两种情况下均发现在多药紫杉醇治疗后多西他赛可体内富集MDR1转导的细胞。两名患者均已完全缓解,并且没有MDR1基因转导的明显不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号